**AMENDMENT TRANSMITTAL LETTER**Docket No.
28069-504
(Formerly: 402090/SkyePharma)Serial No.
09/376,487Filing Date
August 18, 1999Examiner
Edward J. WebmanGroup Art Unit
1617Applicants: Awadhesh K. MISHRA, *et al.*Invention: **INJECTABLE AQUEOUS DISPERSIONS OF PROPOFOL****TO THE COMMISSIONER FOR PATENTS**

Transmitted herewith is an Amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

<u>CLAIMS AS AMENDED</u>					
	Claims Remaining After Amendment	Highest # Previously Paid	# Extra Claims Present	Rate	Additional Fee
Total Claims	56	- 106 =	0	x \$50.00	\$0.00
Independent Claims	6	- 8 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Total					\$0.00
Small Entity Reduction (-50%):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

☒ Large Entity☐ Small Entity☒ No additional fee is required for the Amendment.☐ Please charge Deposit Account No. **50-0311** in the amount of _____
A duplicate copy of this sheet is enclosed.☐ A check in the amount of _____ \$0.00 _____ to cover the fee is enclosed.☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **50-0311**,
Matter: **28069-504**, as described below. A duplicate copy of this sheet is enclosed.☒ Credit any overpayment.☒ Charge any additional filing or application processing fees required under 37 C.F.R. 1.16 and
1.17.

Dated: July 7, 2005

Leslie A. Serunian, Reg. No. 35,353
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO P.C.
The Chrysler Center,
666 Third Avenue, 24th Floor
New York, NY 10017
Tel.: (212) 935-3000
Fax: (212) 983-3115Express Mail Label No.: **EV 591029036US**



07-11-05

1617
ZAWAttorney Docket No.: 28069-504
(Formerly: 402090/SlyePharma)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Awadhesh K. MISHRA, *et al.* Confirmation No. 6585
U.S. Serial No. : 09/376,487 Customer No. : 35437
Filed : August 18, 1999
TC/A.U. : 1617
Examiner : Edward J. Webman
For : **Injectable Aqueous Dispersions of Propofol**

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


EXPRESS MAIL TRANSMITTALDate of Deposit: **July 7, 2005**

I hereby certify that the document(s) listed below are being deposited with the United States Patent and Trademark Office as Express Mail bearing Express Mail Label No. **EV 591029036 US** under 37 C.F.R. §1.10 in an envelope with prepaid postage on the date indicated above and addressed to **Mail Stop Amendment**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450:

1. Amendment In Response to the April 8, 2005 Non-Final Office Action [15 pgs.];
2. Amendment Transmittal Letter (No Fee Due), [1 pg.];
3. Express Mail Transmittal [1 pg.]; and
4. Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (212) 935-3000, New York, New York. The Director is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. **50-0311**, Reference No. **28069-504**, Customer No. **35437**.

Dated: July 7, 2005


Leslie A. Serunian, Reg. No. 35,353
MINTZ LEVIN COHEN FERRIS
GLOVSKY and POPEO, P.C.
The Chrysler Center
666 Third Avenue, 24th Floor
New York, NY 10017
Telephone: (212) 935-3000
Facsimile: (212) 983-3115



PATENT
Docket No.: 28069-504
(Formerly: 402090/SkyePharma)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Awadhesh K. MISHRA *et al.* Confirmation No.: 6585
Serial No. : 09/376,487 Customer No.: 35437
Filed : August 18, 1999
Art Unit : 1617
Examiner : Edward J. Webman
For : **Injectable Aqueous Dispersions of Propofol**

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT IN RESPONSE TO THE APRIL 8, 2005 NON-FINAL OFFICE ACTION

Dear Sir:

This Amendment pursuant to 37 C.F.R. §1.111 is submitted in reply to the April 8, 2005 non-final Office Action received in the above-identified patent application.

Please amend the application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments are found on page 12 of this paper.

A **Conclusion** is found on page 15 of this paper.

Entry and consideration of this responsive amendment are respectfully requested at the time of examination of the subject application.

Express Mail Label No.: EV 591029036US